Treatment of tendon disorders using platelets produced from adipose tissue-derived mesenchymal stem cell line
Patent Information
- Application Number
- PCT/JP2024/028622
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-10
- Filing Date
- 2024-08-09
- Publication Date
- 2025-02-13
Smart Images

Figure 00000052_0000 
Figure 00000052_0001 
Figure 00000052_0002
Abstract
Description
Treatment of tendon disorders using platelets produced from adipose tissue-derived mesenchymal stem cell lines
[0001] The present invention relates to a therapeutic agent for tendon disorders, which contains platelets produced from an adipose tissue-derived mesenchymal stem cell line (ASCL) as an active ingredient.
[0002] Tendinopathy is a chronic inflammation-related disorder of the tendon insertions that move the hands and fingers, including tendinitis and enthesitis. Tendinopathy commonly occurs in the joints of the extremities, including the elbow (lateral epicondylitis (also known as tennis elbow) and medial epicondylitis (also known as golfer's elbow)), heel (Achilles enthesitis), shoulder (tendonitis), and knee (patellar tendinitis). It causes sharp pain during activities such as holding an object, twisting a doorknob, and walking, interfering with work, sports, and everyday activities. Tendinopathy generally results from repetitive movements in work or sports, as well as degeneration and microtears of the tendon insertions due to aging. Once tendinopathy develops, symptoms persist and become intractable, often resulting in years of pain. For this reason, it is sometimes referred to as intractable enthesitis.
[0003] Previous epidemiological studies on lateral epicondylitis (also known as tennis elbow), a common and common form of tendinitis or enthesitis, have shown incidence rates of 1.0-1.3% in men and 1.1-4.0% in women, with the most common ages being between 30 and 50. Of these, 10-20% are difficult to treat and ultimately require surgery. However, poor outcomes have been reported for surgery in patients under 65 due to their high postoperative activity levels. Restrictions on social activities for middle-aged and older men, who are key workers in society, reduce productivity and lead to social losses. This can be inferred from the fact that musculoskeletal disorders accounted for the majority of occupational diseases, at 38.1%, with lateral epicondylitis and digital tendonitis being the most common. Furthermore, from a medical economic perspective, tendon injuries (tendinitis, enthesitis, etc.), such as lateral epicondylitis, are considered to be diseases that cannot be overlooked.
[0004] A wide variety of treatments have been applied to treat tendon disorders, including oral and topical administration of nonsteroidal anti-inflammatory drugs, local steroid injections, physical therapy, ultrasound therapy, extracorporeal shock wave therapy, bracing, and surgical treatment, but no definitive treatment has yet been established. Among these, reports of the effectiveness of PRP (Platelet-Rich-Plasma) therapy for tendon disorders such as tendinitis and enthesitis have recently attracted attention. For example, Patent Document 1 describes a freeze-dried polymer composition to be mixed with PRP (platelet-rich plasma) or blood to form an implant for tissue repair and / or a composition for therapeutic intra-articular injection.
[0005] It is known that administered PRP exerts the aforementioned therapeutic effects by releasing various cytokines. However, the amount of cytokines released by PRP varies greatly depending on the donor from whom blood is collected and on the PRP preparation method used even for the same donor, resulting in significant variation in PRP quality. In particular, due to their unique cell properties, platelets are easily activated by physical stimuli during collection and preparation, leading to cell aggregation, which significantly affects the quality of PRP. Furthermore, the dosage and administration method vary depending on the facility, and no consistent protocol exists. In addition, PRP is difficult to store while maintaining its quality, and it is currently administered immediately after collection without confirming its quality.
[0006] Given this background, it is difficult to conduct clinical research on PRP with a high level of evidence, and even the 2019 Guidelines for the Treatment of Lateral Epicondylitis of the Humerus only rated it at a recommendation level of 2 (weak recommendation), with an evidence level of B (moderate confidence in the estimated effectiveness). Furthermore, even under the Type 3 Regenerative Medicine Provision Plan, which is currently offered as elective medical care, PRP is administered to patients without being verified with strong evidence of effectiveness. This situation is not limited to Japan, but is similar in the United States, where almost all review articles on PRP cite the quality of PRP as a limitation.
[0007] Incidentally, adipose tissue-derived mesenchymal stem cells cultured and proliferated from adipose tissue are known to participate in tissue regeneration through differentiation or to promote tissue regeneration by secreting growth factors. Furthermore, a treatment method in which adipose tissue-derived mesenchymal stem cells (also known as adipose tissue-derived stem cells: ADSCs) are injected into the joints of patients with knee osteoarthritis has been clinically introduced as regenerative medicine worldwide and is also available as an elective treatment in Japan. For example, Patent Document 2 describes the use of adipose tissue-derived mesenchymal stem cells in the treatment of knee osteoarthritis. Knee osteoarthritis is a disease in which the cartilage in the knee joint wears down due to aging or overuse of the knee joint, resulting in joint pain, swelling, and deformation, and is distinct from tendon disorders.
[0008] Meanwhile, the present inventors have previously developed a method for inducing differentiation of adipose precursor cells into megakaryocytes and / or platelets by culturing them in a basal medium for mesenchymal cell culture containing iron ions and an iron transporter (Patent Document 3), and a novel method for producing an adipose tissue-derived mesenchymal stem cell line (ASCL) from vertebrate adipose tissue-derived mesenchymal stem cells (i.e., a novel method for establishing an adipose tissue-derived mesenchymal stem cell line) (Patent Document 4). Furthermore, the present inventors have developed a method for treating wounds by administering to the wound a platelet-like cell population produced from adipose tissue-derived mesenchymal stem cells (e.g., an adipose tissue-derived mesenchymal stem cell line) (Patent Document 5). The present inventors are also working on clinical applications of the technology for producing platelets from ASCL.
[0009] JP-T-2017-506116 A JP-A-2017-93431 A International Publication No. 2014 / 208100 Pamphlet Republished No. 2017 / 094260 JP-A-2019-34917
[0010] In current tendon disorder treatments using PRP, patients generally serve as PRP donors. This current treatment method has several problems. First, PRP treatments have the problem of significant variation in PRP quality due to differences in the individual (donor) from whom blood is drawn and differences in the PRP preparation method. Second, because only small amounts of PRP can be obtained from blood, it is difficult to secure a sufficient amount of PRP. Third, PRP treatments require the invasive procedure of drawing blood from the patient. Furthermore, medical institutions must aseptically prepare PRP from the blood before the PRP's therapeutic activity is lost, and then immediately administer the PRP to the patient. These problems place a heavy burden on both patients and medical institutions.
[0011] An object of the present invention is to provide a therapeutic agent for tendon disorders that uses platelets produced from an adipose tissue-derived mesenchymal stem cell line (ASCL), and that has a stable and excellent therapeutic effect on tendon disorders.
[0012] The present inventors have conducted extensive research to solve the above-mentioned problems, and have found that (a) in tendinopathy model rats, when platelets produced from ASCL are used, IL-6 concentrations are significantly lower and inflammation is significantly suppressed compared to when PRP (platelet-rich plasma) is used, and (b) platelets contained in PRP do not produce TGF-β (a type of anti-inflammatory cytokine) when stimulated with calcium, whereas platelets produced from ASCL do produce TGF-β (a type of anti-inflammatory cytokine) when stimulated with calcium, thereby completing the present invention. Furthermore, it was surprising even for those skilled in the art that platelets produced from ASCL have such remarkable effects compared to platelets derived from blood, such as PRP.
[0013] That is, the present invention includes the following inventions: (1) A therapeutic agent for tendon disorders, the therapeutic agent comprising, as an active ingredient, platelets produced by a production method comprising the following steps (A) to (C): (A) a step of inducing the differentiation of one or more types of cells selected from a stromal vascular cell group including mesenchymal stem cells, preadipocytes, and stromal cells from the adipose tissue of a vertebrate into mature adipocytes; (B) a step of inducing dedifferentiation of the mature adipocytes obtained in step (A) to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line; (C) a step of culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a differentiation-inducing medium into megakaryocytes containing iron ions and an iron transporter, and collecting platelets from the culture; (2) The therapeutic agent according to (1) above, wherein the step of inducing differentiation of one or more types of cells into mature adipocytes in step (A) is a step of culturing the one or more types of cells in a basal medium for mesenchymal cell culture containing one or more types of adipocyte differentiation inducers selected from the group consisting of dexamethasone, isobutylmethylxanthine, insulin, and serum; (3) The therapeutic agent according to (1) or (2) above, wherein inducing dedifferentiation of mature adipocytes in step (B) is ceiling culturing of mature adipocytes; (4) The therapeutic agent according to any of (1) to (3) above, wherein the one or more types of cells are cells obtained by removing mature adipocytes from a cell population obtained by treating adipose tissue of a vertebrate with an enzyme capable of dispersing adipose tissue cells of a vertebrate; (5) The therapeutic agent according to (4) above, wherein the enzyme capable of dispersing adipose tissue cells of a vertebrate is one or more enzymes selected from the group consisting of collagenase, trypsin, caseinase, clostripain, trypsin-EDTA, dispase, thermolysin, pronase, hyaluronidase, pancreatin, elastase, and papain; (6) The therapeutic agent according to any one of (1) to (5) above, wherein the iron transporter in step (C) is transferrin; (7) The therapeutic agent according to any one of (1) to (5) above, wherein the iron ion and iron transporter in step (C) are iron-binding transferrin; (8) The therapeutic agent according to any one of (1) to (7) above, which is administered to the tendon of a vertebrate in need of treatment for tendinopathy;(9) The therapeutic agent according to any one of (1) to (8) above, wherein the tendon disorder is selected from the group consisting of tendinosis, tendinitis, and tenosynovitis; (10) The therapeutic agent according to any one of (1) to (9) above, wherein the tendon disorder is selected from the group consisting of Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis, medial epicondylitis, plantar fasciitis, and rotator cuff tendinopathy; (11) The therapeutic agent according to any one of (1) to (10) above, wherein the vertebrate is a human;
[0014] According to the present invention, it is possible to provide a therapeutic agent for tendon disorders that uses platelets produced from a specific adipose tissue-derived mesenchymal stem cell line (ASCL), and that has a stable and excellent therapeutic effect on tendon disorders. Furthermore, because the platelets of the present invention are prepared from ASCL, they have advantages such as the ability to be mass-cultured and cryopreserved.
[0015] This figure shows the results of RT-PCR analysis of the expression levels of IL-6 (a type of inflammatory cytokine) in the incision-side leg and the sham-side leg in a tendon injury model rat. The values on the vertical axis represent the relative expression levels, with the expression level in the sham-side leg set at 1. "**" in the figure indicates a statistically significant difference (p<0.01) compared to the control group (the same applies below). 1 x 10 8 10 mM CaCl in PBS (phosphate buffered saline) 2Figure 1 shows the results of measuring the amount (pg) of TGF-β released extracellularly into PBS upon platelet activation following stimulation by incubation with PBS for 15 minutes. Figure 2 shows the results of a maximum breaking load test performed on Achilles tendons from an ASCL-PLC-administered group (left leg) and a control (PBS-administered) group (right leg) in a rat tendon degeneration model. The left panel shows the results two weeks after the start of ASCL-PLC or PBS administration, and the right panel shows the results four weeks after the start of ASCL-PLC or PBS administration. The vertical axis of both panels represents the maximum breaking load (N (Newtons)) of the Achilles tendon. Figure 3 shows the results of hematoxylin-eosin (HE) staining of tissue sections of Achilles tendons from an ASCL-PLC-administered group (left leg) and a control (PBS-administered) group (right leg) in a rat tendon degeneration model, which were fixed in formalin. The left column of panels shows the results one week after the start of ASCL-PLC or PBS administration, the center column of panels shows the results two weeks after the start of ASCL-PLC or PBS administration, and the right column of panels shows the results four weeks after the start of ASCL-PLC or PBS administration. This figure shows the results of Achilles tendon tissue sections from the ASCL-PLC-administered group (left leg) and the control (PBS-administered) group (right leg) in a tendon degeneration model rat, fixed with formalin and then stained with Alcian Blue. The left column of panels shows the results one week after the start of ASCL-PLC or PBS administration, the center column of panels shows the results two weeks after the start of ASCL-PLC or PBS administration, and the right column of panels shows the results four weeks after the start of ASCL-PLC or PBS administration. Figure 1 shows the results of staining with Picrosirius Red of tissue sections of Achilles tendons from an ASCL-PLC-administered group (left leg) and a control (PBS-administered) group (right leg) in a rat tendon degeneration model, where the sections were fixed with formalin and then stained with Picrosirius Red. The left panel shows the results one week after the start of ASCL-PLC or PBS administration, the middle panel shows the results two weeks after the start of ASCL-PLC or PBS administration, and the right panel shows the results four weeks after the start of ASCL-PLC or PBS administration.This figure shows the results of calculating Bonar scores from the hematoxylin-eosin staining results in Figure 5 and the Alcian blue staining results in Figure 6, and comparing the results for the control group (PBS-treated group) and the ASCL-PLC-treated group at various weeks after treatment. The solid line represents the results for the ASCL-PLC-treated group, and the dashed line represents the results for the control group (PBS-treated group). The results for the five parameters used to calculate the Bonar score—cell morphology, collagen sequence, cell density, blood vessels, and matrix—are also shown. An asterisk (*) in the figure indicates a statistically significant difference (p<0.05) compared to the control group (PBS-treated group) (the same applies below). This figure shows the results of RT-PCR analysis of the expression levels of tendon-related cytokines (i.e., Col-1, Col-3, SCX, and TNC) in the ASCL-PLC-treated group (left leg) and the control group (PBS-treated group) (right leg) in a tendon degeneration model rat. The values on the vertical axis represent the relative expression levels, with the expression level in the control group (PBS-administered group) set at 1. 1w represents the results 1 week after the start of ASCL-PLC or PBS administration, 2w represents the results 2 weeks after the start of ASCL-PLC or PBS administration, and 4w represents the results 4 weeks after the start of ASCL-PLC or PBS administration. 1 x 10 8 This figure shows the results of measuring the amount of Col-1 in PBS (phosphate-buffered saline) after contacting tenoblasts with PBS (phosphate-buffered saline) containing 1000 ASCL-PLCs or with PBS (control) for 3, 6, or 12 hours. The values on the vertical axis represent the relative expression level, with the expression level in the control group (PBS-administered group) set at 1.
[0016] The present invention includes the following embodiments: [1] a therapeutic agent for tendon disorders (hereinafter also referred to as "the therapeutic agent of the present invention" in this specification), comprising, as an active ingredient, platelets (hereinafter also referred to as "platelets of the present invention" in this specification) produced by a production method (hereinafter also referred to as "the production method of the present invention" in this specification) comprising the following steps (A) to (C): (A) a step of inducing differentiation of one or more cells selected from a stromal vascular cell group comprising mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue into mature adipocytes; (B) a step of inducing dedifferentiation of the mature adipocytes obtained in step (A) to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line (hereinafter also referred to as "the cell line of the present invention" in this specification); (C) a step of culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a differentiation-inducing medium into megakaryocytes containing iron ions and an iron transporter, and collecting platelets from the culture;
[0017] Furthermore, other embodiments of the present invention include: (2) a method for treating tendinopathy, the method comprising administering platelets of the present invention to a subject in need of treatment for tendinopathy; (3) platelets of the present invention for use in treating tendinopathy; (4) use of platelets of the present invention for producing a therapeutic agent for tendinopathy; (5) platelets of the present invention for use as a therapeutic agent for tendinopathy; and the like.
[0018] (Therapeutic Agent of the Present Invention) The therapeutic agent of the present invention is not particularly limited as long as it is a therapeutic agent for tendon disorders and contains, as an active ingredient, platelets produced by a production method comprising the following steps (A) to (C): (A) a step of inducing the differentiation of one or more types of cells selected from a stromal vascular cell group containing mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue into mature adipocytes; (B) a step of inducing dedifferentiation of the mature adipocytes obtained in step (A) to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line; (C) a step of culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a differentiation-inducing medium into megakaryocytes containing iron ions and an iron transporter, and collecting platelets from the culture;
[0019] The mature adipocytes obtained by the differentiation induction in step (A) are mature adipocytes that are more susceptible to dedifferentiation than mature adipocytes present in vertebrate adipose tissue (hereinafter also referred to as "easily dedifferentiated mature adipocytes" in this specification). Therefore, it is believed that the dedifferentiation induction in step (B) enables the production (establishment) of vertebrate adipose tissue-derived mesenchymal stem cell lines (ASCLs) more simply, in a shorter period of time, and more efficiently. Furthermore, the inventors have already confirmed that ASCLs produced from easily dedifferentiated mature adipocytes (i.e., ASCLs produced by a method comprising steps (A) and (B) of the present invention) are different in terms of cells from adipose tissue-derived mesenchymal stem cell lines produced by directly inducing dedifferentiation of mature adipocytes obtained from vertebrate adipose tissue. As used herein, "ASCLs" refers to adipose tissue-derived mesenchymal stem cell lines produced by a method comprising steps (A) and (B) of the present invention. The production method of the present invention, comprising the above steps (A) to (C), can be an ex vivo or in vitro production method.
[0020] (Platelets in the Present Invention) The platelets in the present invention are not particularly limited as long as they are platelets produced by a production method (production method in the present invention) comprising the above steps (A) to (C). The production method in the present invention is not particularly limited as long as it is a production method comprising the above steps (A) to (C).
[0021] (Step A) The above step (A) is not particularly limited as long as it is a step of inducing the differentiation of one or more types of cells selected from a group of stromal vascular cells including mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue (also referred to herein as "mesenchymal stem cells, etc.") into mature adipocytes. Such a differentiation induction step is a step of inducing differentiation ex vivo or in vitro.
[0022] The biological species from which adipose tissue is derived is not particularly limited as long as it is a vertebrate, and examples thereof include mammals, birds, reptiles, amphibians, fish, etc., with preferred examples including mammals such as humans, mice, rats, guinea pigs, rabbits, cats, dogs, horses, cows, monkeys, sheep, goats, and pigs, with humans being particularly preferred. Furthermore, from the viewpoint of minimizing rejection reactions and the like, the adipose tissue of a vertebrate may be used in the production method of the cell line of the present invention.
[0023] As used herein, "adipose tissue" is not particularly limited as long as it is a tissue containing fat, and examples include subcutaneous adipose tissue, adipose tissue in bone marrow, and visceral adipose tissue. However, subcutaneous adipose tissue is preferred because it is relatively less invasive to the vertebrate that supplies the adipose tissue and is relatively easy to collect.
[0024] As used herein, "stromal vascular cells" refers to cells in vertebrate adipose tissue other than mature adipocytes. Stromal vascular cells typically include mesenchymal stem cells, preadipocytes, stromal cells, vascular endothelial cells, blood-related cells, smooth muscle cells, fibroblasts, and other cells. Such "stromal vascular cells" can be obtained by treating vertebrate adipose tissue with an enzyme capable of dissociating vertebrate adipose tissue cells, and then removing mature adipocytes from the resulting cell population.
[0025] The above-mentioned "one or more types of cells selected from a stromal vascular fraction comprising mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue" is not particularly limited as long as it is one or more types of cells selected from a stromal vascular fraction comprising mesenchymal stem cells, preadipocytes (or adipose progenitor cells), and stromal cells of vertebrate adipose tissue. However, from the viewpoint of more efficiently producing a vertebrate adipose tissue-derived mesenchymal stem cell line, a cell population comprising at least preadipocytes and mesenchymal stem cells and / or stromal cells is preferred over a cell population consisting only of preadipocytes, a cell population comprising at least preadipocytes, mesenchymal stem cells, and stromal cells is more preferred, and a cell population comprising at least preadipocytes, mesenchymal stem cells, and stromal cells is even more preferred because of its ease of preparation.
[0026] Furthermore, a preferred embodiment of the above-mentioned "one or more types of cells selected from a stromal vascular cell group comprising mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue" includes one or more types of cells selected from a stromal vascular cell group comprising mesenchymal stem cells, preadipocytes, and stromal cells obtained by dispersing cells from vertebrate adipose tissue. A preferred example is a cell population (cell population A) obtained by removing mature adipocytes from a cell population obtained by treating vertebrate adipose tissue with an enzyme capable of dispersing vertebrate adipose tissue cells. Alternatively, a cell population obtained by further removing vascular endothelial cells and / or blood-related cells from such cell population A may also be used. The cells (cell population A) obtained by removing mature adipocytes and the like from a cell population obtained by treating vertebrate adipose tissue with an enzyme capable of dispersing vertebrate adipose tissue cells described above are a cell population of stromal vascular cells, which typically contain cells such as mesenchymal stem cells, preadipocytes, stromal cells, vascular endothelial cells, blood-related cells, smooth muscle cells, and fibroblasts from vertebrate adipose tissue.
[0027] The above-mentioned method of "treating vertebrate adipose tissue with an enzyme capable of dispersing vertebrate adipose tissue cells" includes, for example, a method in which vertebrate adipose tissue is immersed in a solution containing the enzyme and incubated for, for example, about 30 minutes to 3 hours.
[0028] The above-mentioned "enzyme capable of dispersing vertebrate adipose tissue cells" is not particularly limited as long as it is an enzyme capable of dispersing vertebrate adipose tissue cells by acting on the adipose tissue of a vertebrate, and examples thereof include one or more enzymes selected from the group consisting of collagenase, trypsin, caseinase, clostripain, trypsin-EDTA, dispase, thermolysin, pronase, hyaluronidase, pancreatin, elastase, and papain. Of these, one or more enzymes selected from the group consisting of collagenase, trypsin, caseinase, and clostripain are preferred, with commercially available collagenase (type I) and collagenase (type II) being more preferred, and collagenase (type II) being even more preferred. Furthermore, the above-mentioned "enzyme capable of dispersing vertebrate adipose tissue cells" preferably includes at least collagenase.
[0029] The above-mentioned method of "removing mature adipocytes from a cell population obtained by treating vertebrate adipose tissue with an enzyme capable of dispersing vertebrate adipose tissue cells" is not particularly limited as long as it is a method that can remove mature adipocytes from such a cell population, but a preferred example is a method of recovering a cell population (cell pellet) that precipitates when a suspension containing the above-mentioned cell population is centrifuged. Mature adipocytes contain a large amount of fat, so their specific gravity is low and they float to the top of the supernatant when centrifuged, and therefore, by recovering the cell pellet that precipitates by such centrifugation, mature adipocytes can be removed. Furthermore, methods for removing vascular endothelial cells, smooth muscle cells, and fibroblasts from a cell population obtained by treating vertebrate adipose tissue with an enzyme capable of dispersing vertebrate adipose tissue cells are not particularly limited as long as they are capable of removing these cells from the cell population. Examples include a method of removing vascular endothelial cells from the cell population by selecting cells that are negative for CD31, which is known as a surface marker for vascular endothelial cells (or removing CD31-positive cells). Methods for removing blood-related cells from a cell population include a method of removing blood-related cells from the cell population by selecting cells that are negative for CD45 (a surface marker for hematopoietic cells other than erythrocytes and platelets) and Ter119 (a surface marker for erythrocytes and their precursor cells) (or removing CD45-positive and Ter119-positive cells). Furthermore, although not a cell surface marker, using 7-amino-actinomycin D (7-AAD) negativity as an indicator is preferred because it allows for the elimination of dead cells contained in vertebrate adipose tissue. 7-AAD intercalates into the DNA strands of dead cells and emits red fluorescence when excited by 488 nm light.
[0030] The precipitated cell pellet (cell population A) is a stromal vascular cell population, which typically includes mesenchymal stem cells, preadipocytes, stromal cells (stromal cells), vascular endothelial cells, smooth muscle cells, fibroblasts, etc., but only mesenchymal stem cells, preadipocytes, and stromal cells can differentiate into mature adipocytes. Therefore, a step of removing one, two, or all of the types of cells other than these three types from the precipitated cell pellet may be included, for example, prior to inducing differentiation into mature adipocytes. This step is optional, and from the standpoint of ease of operation, it is preferable not to include such a step. Even when vascular endothelial cells, smooth muscle cells, and fibroblasts are subjected to induction of differentiation into mature adipocytes together with mesenchymal stem cells, etc., they do not differentiate into mature adipocytes, nor do they interfere with the differentiation of mesenchymal stem cells, etc., into mature adipocytes.
[0031] In the above step (A), a preferred method for inducing the differentiation of one or more cells selected from the stromal vascular cell group containing mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue into mature adipocytes is to culture one or more cells selected from the stromal vascular cell group containing mesenchymal stem cells, preadipocytes, and stromal cells of vertebrate adipose tissue in a basal medium for mesenchymal cell culture containing an adipocyte differentiation inducer. The method for culturing mesenchymal stem cells or the like in a basal medium for mesenchymal cell culture containing an adipocyte differentiation inducer is not particularly limited, as long as such culture can induce the differentiation of mesenchymal cells into mature adipocytes. For example, a method similar to a conventional method for inducing the differentiation of preadipocytes into mature adipocytes can be used, i.e., a method for culturing starting cells in a basal medium for mesenchymal cell culture containing an adipocyte differentiation inducer.
[0032] In step (A) above, conditions for culturing mesenchymal stem cells or the like in a basal mesenchymal cell culture medium containing an adipocyte differentiation inducer include, for example, adhesion culture in a culture vessel coated with an extracellular matrix. The culture temperature is typically within the range of 12 to 45°C, preferably 15 to 37°C. The culture period, from the viewpoint of balancing the efficient production of vertebrate adipose tissue-derived mesenchymal stem cell lines with a short production time, is within the range of 5 to 16 days, preferably 7 to 14 days, more preferably 8 to 12 days, even more preferably 9 to 11 days, and more preferably 10 days. In such culture, mesenchymal stem cells or the like may or may not be passaged. Furthermore, the extracellular matrix may include one or more components selected from collagen, fibronectin, proteoglycan, and laminin. BD Matrigel® (manufactured by BD Biosciences) containing such components may also be used.
[0033] The adipocyte differentiation inducer is not particularly limited as long as it has the effect of differentiating cells capable of being induced to differentiate into mature adipocytes into mature adipocytes or the effect of supporting this action, and examples thereof include one or more selected from the group consisting of dexamethasone, isobutylmethylxanthine, insulin, and serum. From the viewpoint of obtaining a more excellent efficiency of inducing differentiation into mature adipocytes, preferred examples thereof include "a combination of serum and dexamethasone," "a combination of serum and an adipocyte differentiation inducer containing at least dexamethasone," "a combination of serum and isobutylmethylxanthine," and "a combination of serum and an adipocyte differentiation inducer containing at least isobutylmethylxanthine." Of these, "a combination of serum, dexamethasone, and insulin" is particularly preferred. "A combination of an adipocyte differentiation inducer comprising at least serum, dexamethasone, and insulin," "a combination of serum, isobutylmethylxanthine, and insulin," "a combination of an adipocyte differentiation inducer comprising at least serum, isobutylmethylxanthine, and insulin," "a combination of serum, dexamethasone, and isobutylmethylxanthine," and "a combination of an adipocyte differentiation inducer comprising at least serum, dexamethasone, and isobutylmethylxanthine" are more preferred, and among these, "a combination of serum, dexamethasone, isobutylmethylxanthine, and insulin" and "a combination of an adipocyte differentiation inducer comprising at least serum, dexamethasone, isobutylmethylxanthine, and insulin" are even more preferred. The adipocyte differentiation inducer and the basal culture medium for mesenchymal cell culture containing said substance may be commercially available, or such a culture medium may be prepared by adding the adipocyte differentiation inducer to a basal culture medium for mesenchymal cell culture. A preferred example of a commercially available culture medium containing an adipocyte differentiation inducer is Adipocyte Differentiation Medium (manufactured by Cell Applications, Inc.) Other than the adipocyte differentiation inducers listed above, examples of substances that assist differentiation into mature adipocytes include rosiglitazone, pioglitazone, and indomethacin.
[0034] The concentration of the adipocyte differentiation inducer in the culture medium is not particularly limited as long as it can induce differentiation of mesenchymal stem cells and the like into mature adipocytes, but typically, the dexamethasone concentration is in the range of 0.1 to 10 μM, preferably in the range of 0.5 to 2.5 μM; the isobutylmethylxanthine concentration is in the range of 10 to 1000 μM, preferably in the range of 250 to 750 μM; the insulin concentration is in the range of 0.1 to 10 μM, preferably in the range of 0.5 to 2.5 μM; and the serum concentration is in the range of 1 to 20 wt %, preferably in the range of 5 to 15 wt %, more preferably in the range of 7 to 13 wt %.
[0035] The "basal culture medium for mesenchymal cell culture" as used herein is not particularly limited as long as it is a culture medium that can proliferate mesenchymal cells by culturing at least one type of mesenchymal cells in the culture medium. However, a chemically synthesized culture medium is preferred in terms of ease of preparation and prevention of lot-to-lot variation, and preferably contains one or more types of sugar(s), one or more types of inorganic salt(s), one or more types of amino acid(s), and one or more types of vitamin(s), and optionally one or more types of other components.
[0036] Specific examples of the sugars include monosaccharides such as glucose, mannose, fructose, and galactose, and disaccharides such as sucrose, maltose, and lactose. Among these, glucose is particularly preferred, and these sugars can also be added in combination of one or more.
[0037] Specific examples of the inorganic salts include one or more inorganic salt(s) selected from calcium chloride, calcium nitrate, copper sulfate pentahydrate, iron (III) nitrate nonahydrate, iron (II) sulfate heptahydrate, magnesium chloride hexahydrate, magnesium sulfate, potassium chloride, sodium chloride, sodium hydrogen carbonate, disodium hydrogen phosphate, disodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, sodium dihydrogen phosphate dihydrate, sodium selenite pentahydrate, and zinc sulfate heptahydrate.
[0038] Specific examples of the amino acids include one or more amino acids selected from alanine, arginine, asparagine, aspartic acid, cystine, cysteine, glutamine, glycine, histidine, glutamic acid, hydroxyproline, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, etc., preferably L-amino acids, and derivatives thereof, salts thereof, and hydrates thereof. For example, the arginine may be an arginine derivative such as L-arginine hydrochloride or L-arginine monohydrochloride; the aspartic acid may be an aspartic acid derivative such as L-aspartic acid sodium salt monohydrate, L-aspartic acid monohydrate, potassium L-aspartate or magnesium L-aspartate; and the cysteine may be a cysteine derivative such as L-cysteine dihydrochloride or L-cysteine hydrochloride monohydrate, or a lysine derivative such as L-lysine hydrochloride. The glutamic acid may include glutamine derivatives such as L-glutamic acid monosodium salt, the asparagine may include asparagine derivatives such as L-asparagine monohydrate, the tyrosine may include tyrosine derivatives such as L-tyrosine disodium dihydrate, the histidine may include histidine derivatives such as histidine hydrochloride and histidine hydrochloride monohydrate, and the lysine may include lysine derivatives such as L-lysine hydrochloride.
[0039] Specific examples of the vitamins include one or more vitamin(s) selected from biotin, choline, folic acid, inositol, niacin, pantothenic acid, pyridoxine, riboflavin, thiamine, vitamin B12, para-aminobenzoic acid (PABA), and ascorbic acid, as well as derivatives of each of these components, their salts, and their hydrates. For example, the choline may be a choline derivative such as choline chloride; the niacin may be a niacin derivative such as nicotinic acid, nicotinamide, or nicotinic alcohol; the pantothenic acid may be a pantothenic acid derivative such as calcium pantothenate, sodium pantothenate, or panthenol; the pyridoxine may be a pyridoxine derivative such as pyridoxine hydrochloride, pyridoxal hydrochloride, pyridoxal phosphate, or pyridoxamine; the thiamine may be a thiamine derivative such as thiamine hydrochloride, thiamine nitrate, bisthiamine nitrate, thiamine dicetyl sulfate, fursultiamine hydrochloride, octotiamine, or benfotiamine; and the ascorbic acid may be an ascorbic acid derivative such as ascorbic acid 2-phosphate, magnesium ascorbyl phosphate, sodium ascorbyl sulfate, ascorbyl aminopropyl phosphate, or sodium ascorbyl phosphate.
[0040] Examples of the other components include buffers such as HEPES, antibiotics such as penicillin and streptomycin, pyruvic acid, derivatives thereof, salts thereof, and hydrates thereof, and phenol red. Preferred examples of the antibiotic derivatives include sodium penicillin G, streptomycin sulfate, and a penicillin-streptomycin solution. Preferred examples of the pyruvic acid derivatives include sodium pyruvate.
[0041] Specific examples of the basal culture medium for mesenchymal cell culture include commercially available chemically synthesized culture media such as Dulbecco's Modified Eagle's Medium (DMEM), Iscove's Modified Dulbecco's Medium (IMDM), RPMI1640 culture medium, minimal essential medium (MEM), basal Eagle's medium (BME), and F12 culture medium, as well as culture media prepared by mixing two or more of these culture media in an appropriate ratio, such as DMEM / F12 culture medium (a culture medium prepared by mixing DMEM and F12 culture media in a 1:1 ratio), and any of these culture media supplemented with antibiotics such as penicillin and streptomycin; and additional amino acids (preferably non-essential amino acids). Preferred examples of such a culture medium include a culture medium further supplemented with one or more substances selected from the group consisting of: amino acids; and in particular, a culture medium further supplemented with an antibiotic (preferably penicillin G sodium, streptomycin sulfate, or a penicillin-streptomycin solution) in a DMEM, IMDM, or RPMI 1640 culture medium, and particularly preferred examples of such a culture medium include a culture medium further supplemented with an antibiotic (preferably penicillin G sodium, streptomycin sulfate, or a penicillin-streptomycin solution) in a DMEM.
[0042] Particularly preferred basal culture media for mesenchymal cell culture in the present invention include a culture medium in which 100 U / mL (final concentration) of penicillin-streptomycin solution is added to DMEM having the composition described below (hereinafter referred to as a "particularly preferred basal culture medium in the present invention"), and a culture medium containing each component independently at a concentration within the range of 70% to 130% (preferably within the range of 80 to 120% by weight) of the concentration of each component in the particularly preferred basal culture medium in the present invention.
[0043] (Composition of DMEM) 200 mg / L anhydrous calcium chloride, 0.1 mg / L Fe(NO 3 ) 3 ・9H 2O, 200 mg / L potassium chloride, 97.67 mg / L magnesium sulfate anhydrous, 6400 mg / L sodium chloride, 3700 mg / L sodium bicarbonate, 125 mg / L sodium dihydrogen phosphate monohydrate, 4500 mg / L D-glucose, 15 mg / L phenol red, 110 mg / L sodium pyruvate, 84 mg / L L-arginine hydrochloride, 63 mg / L L-cystine dihydrochloride, 584 mg / L L-glutamine, 30 mg / L glycine, 42 mg / L L-histidine hydrochloride monohydrate, 105 mg / L L-isoleucine, 105 mg / L L-leucine, 146 mg / L L-lysine hydrochloride, 30 mg / L L-methionine, 66 mg / L L-phenylalanine, 42 mg / L L-serine, 95 mg / L L-threonine, 16 mg / L L-tryptophan, 104 mg / L L-tyrosine disodium dihydrate, 94 mg / L L-valine, 4 mg / L D-calcium pantothenate, 4 mg / L choline chloride, 4 mg / L folic acid, 7.2 mg / L i-inositol, 4 mg / L nicotinamide, 4 mg / L pyridoxine hydrochloride, 0.4 mg / L riboflavin, 4 mg / L thiamine hydrochloride.
[0044] The mature adipocytes obtained by step (A) (i.e., a mature adipocyte population containing mature adipocytes) are easily dedifferentiated mature adipocytes that are relatively susceptible to dedifferentiation when induced to dedifferentiate (i.e., a easily dedifferentiated mature adipocyte population containing easily dedifferentiated mature adipocytes). As used herein, "easily dedifferentiated mature adipocyte population" refers to a mature adipocyte population in which the proportion of cell lines obtained is 1.5 times or more, as compared to a mature adipocyte population collected from vertebrate adipose tissue as in the conventional method (Japanese Patent No. 5055611), and preferably includes a mature adipocyte population in which the proportion is 2 times or more, more preferably 4 times or more, even more preferably 6 times or more, more preferably 10 times or more, and even more preferably 15 times or more. The "proportion of cell lines obtained" refers to the proportion of cell lines obtained from a specific amount of mature adipocyte population, and such proportion preferably includes, for example, the ratio (ratio) of the "weight of the obtained cell lines" to the "weight of the mature adipocytes used to induce dedifferentiation."
[0045] (Step B) The above step (B) is not particularly limited as long as it is a step of inducing dedifferentiation of the mature adipocytes (easily dedifferentiated mature adipocytes) obtained in step (A) to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line. Such a step may be an ex vivo or in vitro step.
[0046] The mature adipocytes used in step (B) are mature adipocytes obtained by differentiation induction in step (A). Such mature adipocytes can be obtained, for example, by centrifuging the culture suspension of step (A) and recovering the cells floating at the top of the supernatant. This is because mature adipocytes contain a large amount of fat and therefore have a low specific gravity, so they float at the top of the supernatant when centrifuged.
[0047] In the above step (B), the method of inducing dedifferentiation of the mature adipocytes (easily dedifferentiated mature adipocytes) obtained in step (A) to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line is not particularly limited as long as it is a method of inducing dedifferentiation of such mature adipocytes to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line, but a preferred example is a method of so-called ceiling culture of such mature adipocytes. Ceiling culture is a method of culturing cells by adhering or floating (preferably by adhering) them to the inner upper surface (ceiling surface) of a culture vessel (preferably a culture flask) filled with culture medium, and takes advantage of the property of mature adipocytes that they contain a large amount of fat, have a low specific gravity, and therefore float in the culture medium.
[0048] Examples of culture media for dedifferentiation-inducing and culturing mature adipocytes include basal culture media for mesenchymal cell culture containing an extracellular matrix. Such extracellular matrix may include one or more components selected from collagen, fibronectin, proteoglycan, laminin, and serum (e.g., FBS). BD Matrigel (registered trademark) (manufactured by BD Biosciences) containing such components may also be used. Serum such as FBS in the culture media for dedifferentiation-inducing and culturing mature adipocytes may be used solely as an adhesion factor for adhering the mature adipocytes to the ceiling surface of the culture vessel, or may not be used solely as an adhesion factor for this purpose. The culture media for dedifferentiation-inducing and culturing mature adipocytes may not contain serum such as FBS, but from the perspective of more efficiently producing vertebrate adipose tissue-derived mesenchymal stem cell lines, it is preferable to contain serum such as FBS together with or without an extracellular matrix other than serum. When such a culture medium contains serum such as FBS, the serum concentration is not particularly limited as long as a vertebrate adipose tissue-derived mesenchymal stem cell line can be obtained, but can be in the range of 3 to 30% by weight, preferably in the range of 7 to 25% by weight, and more preferably in the range of 7 to 13% by weight.
[0049] In the above step (B), among the conditions for culturing mature adipocytes in a basal medium for mesenchymal cell culture containing an extracellular matrix, conditions other than ceiling culture include a culture temperature typically in the range of 12 to 45°C, preferably 15 to 37°C, and a culture period in the range of 2 to 28 days, preferably 4 to 21 days, more preferably 5 to 14 days, even more preferably 6 to 10 days, and more preferably 7 days, from the viewpoint of balancing the efficient production of vertebrate adipose tissue-derived mesenchymal stem cell lines with the production in a shorter period of time. Note that in such culture, mature adipocytes and the like do not need to be passaged, but may be passaged.
[0050] In the above step (B), vertebrate adipose tissue-derived mesenchymal stem cell lines may or may not be isolated from the culture medium after ceiling culture, but isolation is preferred. By continuing such ceiling culture, the established adipose tissue-derived mesenchymal stem cell lines actively proliferate while mature adipocytes gradually decrease, thereby obtaining a cell population rich in adipose tissue-derived mesenchymal stem cell lines. For example, by continuing ceiling culture for about 14 days, a cell population rich in adipose tissue-derived mesenchymal stem cell lines can be obtained.
[0051] For convenience, performing ceiling culture in the above step (B) also includes continuing the culture after the mature adipocytes (easily dedifferentiated mature adipocytes) obtained in step (A) have adhered to the ceiling surface of the culture vessel, by positioning the culture vessel so that the adhesive surface is on the underside of the culture vessel. However, it is also possible to obtain an adipose tissue-derived mesenchymal stem cell line without performing the culture in which the mature adipocytes (easily dedifferentiated mature adipocytes) obtained in step (A) are continued to be cultured while adhering to the ceiling surface of the culture vessel and the culture vessel is positioned so that the adhesive surface is on the underside of the culture medium.
[0052] The adipose tissue-derived mesenchymal stem cell line (ASCL) produced by the method of the present invention comprising steps (A) and (B) is not particularly limited as long as it is a vertebrate adipose tissue-derived mesenchymal stem cell line produced by the method of the present invention comprising steps (A) and (B), but ASCL owned by Heartseed Co., Ltd. is particularly preferred. The ASCL of the present invention do not undergo spontaneous differentiation when cultured in a conventional basal medium for mesenchymal cell culture that does not have a differentiation-inducing effect, and are capable of long-term subculture. Even after long-term subculture, they maintain their proliferation ability and their ability to differentiate into mesodermal cells (one or more types selected from the group consisting of megakaryocytes / platelets, osteoblasts, chondrocytes, and adipocytes). For example, ASCL of the present invention produced from human subcutaneous adipose tissue maintain their proliferation ability even at the 20th passage, and a doubling time of 23 hours has been observed.
[0053] It is preferred that ASCL of the present invention express one or more surface markers (preferably three or more, more preferably five or more, even more preferably seven or more, more preferably eight or nine, and most preferably nine) selected from the following group of surface markers for mesenchymal cells, and do not express one or more surface markers (preferably three or more, more preferably five or more, even more preferably seven or more, more preferably eight or nine, and most preferably nine) selected from the following group of surface markers for blood cells: mesenchymal cell surface markers: CD13, CD29, CD44, CD71, CD73, CD90, CD105, CD166, HLA-ABC; blood cell surface markers: CD11b, CD14, CD19, CD34, CD41, CD42b, CD45, CD56, HLA-DR;
[0054] The International Society for Cell Therapy defines mesenchymal stem cells as follows: (a) they are adherent cells, (b) they can differentiate into bone, cartilage, or fat, and (c) they express surface markers for mesenchymal cells but do not express surface markers for blood cells. Among the ASCLs of the present invention, a preferred embodiment of the cell line satisfies these conditions (a), (b), and (c).
[0055] The ASCLs of the present invention can be grown by culturing them in a mesenchymal stem cell growth medium. Commercially available mesenchymal stem cell growth medium can be used.
[0056] (Step C) The above step (C) is not particularly limited, as long as it involves culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a differentiation-inducing medium containing iron ions and an iron transporter into megakaryocytic cells, and collecting platelets from the culture. Such differentiation-inducing step is an ex vivo or in vitro differentiation-inducing step. The mechanism by which platelets are produced from ASCLs of the present invention when cultured in a differentiation-inducing medium containing iron ions and an iron transporter into megakaryocytic cells is unclear, but it is thought that iron ions taken up into the ASCL, or iron ions and iron transporters, promote thrombopoietin (TPO) secretion from the cells through some mechanism, which in turn promotes the induction of ASCL differentiation into platelets.
[0057] The "culture medium for inducing differentiation into megakaryocytic cells, containing iron ions and an iron transporter" in step (C) (hereinafter also referred to as "culture medium in step (C)") is a culture medium in which iron ions and an iron transporter are added to a basal culture medium for mesenchymal cell culture. The addition of iron ions and an iron transporter induces the differentiation of ASCLs into platelets.
[0058] The iron ion may be either iron (II) ion or iron (III) ion, with iron (III) ion being preferred. A method for incorporating iron ions into the culture solution in step (C) includes adding one or more iron salts selected from the group consisting of inorganic and organic iron salts to the culture solution for inducing differentiation into megakaryocytic cells. Such iron salts may be organic or inorganic salts, and examples of the inorganic salts include iron chloride (II), iron chloride (III), iron oxide (II), iron oxide (III), iron nitrate (II), iron nitrate (III), iron sulfate (II), iron sulfate (III), ammonium iron sulfate (II), ammonium iron sulfate (III), iron pyrophosphate (II), iron pyrophosphate (III), iron sulfide (II), iron sulfide (III), iron hydroxide (II), and iron hydroxide (III). Examples of the organic salts include iron acetate (II), iron acetate (III), hydroxydiacetoxyiron (III), iron citrate (II), iron citrate (III), sodium iron citrate (III), ammonium iron citrate (III), iron benzoate (II), iron benzoate (III), carbonate, and the like. Examples of suitable iron salts include iron(II), iron(III), formate(II), formate(III), oxalate(II), oxalate(III), fumarate(II), fumarate(III), succinate(II), succinate(III), gluconate(II), gluconate(III), lactate(II), lactate(III), maleate(II), maleate(III), sodium iron(III) diethylenetriaminepentaacetate, ammonium iron(III) diethylenetriaminepentaacetate, sodium iron(III) ethylenediaminetetraacetate, ammonium iron(III) ethylenediaminetetraacetate, sodium iron(III) dicarboxymethylglutamate, and ammonium iron(III) dicarboxymethylglutamate. These iron salts may be used alone or in combination of two or more. Commercially available iron salts may be used.
[0059] The iron transporter binds to iron ions contained in the culture medium in step (C), providing ASCL with the ability to take up iron ions from the culture medium. Furthermore, when an iron transporter bound to iron ions is used, it can also function as an iron source. Iron transporters are sometimes called apo-type when not bound to iron, holo-type when bound to iron, and sidero-type when bound to an amount of iron intermediate between the apo-type and holo-type. Examples of the iron transporter include proteins that bind to iron and are taken up into cells (see, for example, JP 08-029429 A, JP 2005-517042 A, JP 2004-505932 A, and JP 2007-508026 A). Examples of apo-type or equivalent iron transporters include apotransferrin (apocerotransferrin), apolactoferrin, apoovotransferrin, apomelanotransferrin, apoferritin, and protoporphyrin IX, with apotransferrin being preferred. The biological species from which such iron transporters are derived is preferably the same as that from which the mesenchymal cells used together are derived.
[0060] As the iron ion and iron transporter in the present invention, a complex formed by binding of an iron ion and an iron transporter (iron ion-iron transporter complex) can be preferably used. Examples of such iron ion-iron transporter complexes include holotransferrin (iron-binding transferrin) in which apotransferrin is bound to an iron ion, hololactoferrin (iron-binding lactoferrin) in which apolactoferrin is bound to an iron ion, holovotransferrin (iron-binding ovotransferrin) in which apoovotransferrin is bound to an iron ion, holomelanotransferrin (iron-binding melanotransferrin) in which apomelanotransferrin is bound to an iron ion, holoferritin (iron-binding ferritin) in which apoferritin is bound to an iron ion, and heme in which protoporphyrin IX is bound to iron. Among these, iron-binding transferrin is particularly preferred. The above-mentioned holo-type iron transporters that are bound to iron ions, apo-type iron transporters that are not bound to iron ions, and sidero-type iron transporters that are bound to an amount of iron at an intermediate level between the apo-type and holo-type can be commercially available.
[0061] The bond between the iron ion and the iron transporter in the iron ion-iron transporter complex is not particularly limited, and may be a non-covalent bond such as a coordinate bond, ionic bond, hydrogen bond, metallic bond, or van der Waals force, or a covalent bond. However, a coordinate bond is preferred because it provides an appropriate degree of bond and is suitable for transporting iron ions into ASCL. For convenience, the iron ion-iron transporter complex of the present invention also includes complexes in which iron is not in an ionic state but which can release iron ions when the complex is taken up into ASCL.
[0062] The iron ion concentration in the culture medium in step (C) is not particularly limited as long as the platelets of the present invention can be produced by culturing ASCLs in the culture medium used in the present invention having such an iron concentration. Examples of the iron ion concentration include a range of 1 pg / mL to 10 μg / mL, preferably a range of 10 pg to 1 μg / mL, more preferably a range of 150 pg / mL to 300 pg / mL, and even more preferably a range of 150 pg / mL to 250 pg / mL.
[0063] The content of the iron transporter in the culture medium in step (C) is not particularly limited as long as it is a culture medium that can produce the platelets of the present invention by culturing ASCL in the culture medium used in the present invention containing such an iron transporter. For example, -15 The concentration range is preferably 100 fM to 10 nM, more preferably 1 pM to 2.8 pM, and even more preferably 1 pM to 2.5 pM.
[0064] Furthermore, when iron-binding transferrin is used in the culture medium in step (C), its concentration is not particularly limited and may be within the above-mentioned range of iron ion concentration, for example, 25 μg / mL to less than 400 μg / mL, preferably 50 μg / mL to less than 200 μg / mL. Note that approximately 1.3 μg of iron ions are said to be bound to 1 mg of iron-binding transferrin.
[0065] The culture medium in step (C) is not particularly limited as long as it is a culture medium that, when the iron ions and iron transporter of the present invention are added, allows the platelets of the present invention to be produced by culturing ASCLs in the culture medium. However, a chemically synthesized culture medium is preferred in terms of ease of preparation and prevention of lot-to-lot variation, and preferably contains one or more types of sugar(s), one or more types of inorganic salt(s), one or more types of amino acid(s), one or more types of vitamin(s), and one or more types of other components.
[0066] As described above, the culture medium in step (C) (culture medium for inducing differentiation into megakaryocytic cells) is a culture medium obtained by adding iron ions and an iron transporter to a basal culture medium for mesenchymal cell culture capable of culturing mesenchymal cells. Specific examples of suitable basal culture medium for mesenchymal cell culture used in step (C) include commercially available chemically synthesized culture mediums such as Iscove's Modified Dulbecco's Medium (IMDM), RPMI 1640 culture medium, Dulbecco's Modified Eagle's Medium (DMEM), Minimum Essential Medium (MEM), Basal Eagle's Medium (BME), and F12 culture medium, as well as culture mediums prepared by mixing two or more of these culture mediums in an appropriate ratio, such as DMEM / F12 culture medium (a culture medium prepared by mixing DMEM and F12 culture medium at a 1:1 ratio), and culture mediums prepared by adding nucleic acids such as nucleotides, penicillin, streptomycin, etc. to any of these culture mediums. Preferred examples include culture media further supplemented with an antibiotic (preferably penicillin G sodium, streptomycin sulfate, or a penicillin-streptomycin solution) and L-glutamine, and more preferred examples include culture media further supplemented with an antibiotic (preferably penicillin G sodium, streptomycin sulfate, or a penicillin-streptomycin solution) and L-glutamine in IMDM or RPMI 1640 culture media. Of these, particularly preferred examples include culture media further supplemented with an antibiotic (preferably penicillin G sodium, streptomycin sulfate, or a penicillin-streptomycin solution) and L-glutamine in IMDM.
[0067] Particularly suitable basal culture medium for mesenchymal cell culture to be used as the culture medium in step (C) includes a culture medium in which 2 mM (final concentration) of L-glutamine and 100 U / mL (final concentration) of penicillin-streptomycin solution are added to IMDM having a composition described below (hereinafter referred to as a "particularly suitable basal culture medium to be used as the culture medium in step (C)"), and a culture medium containing each component independently at a concentration within the range of 70 to 130% by weight (preferably within the range of 80 to 120% by weight) of the concentration of each component in the particularly suitable basal culture medium to be used as the culture medium in step (C).
[0068] (Composition of IMDM) 0.4 mM glycine, 0.281 mM L-alanine, 0.398 mM L-arginine hydrochloride, 0.167 mM L-asparagine, 0.226 mM L-aspartic acid, 0.381 mM L-cystine dihydrochloride, 0.51 mM L-glutamic acid, 4 mM L-glutamine, 0.2 mM L-histidine hydrochloride monohydrate, 0.802 mM L-isoleucine, 0.802 mM L-leucine, 0.798 mM L-lysine hydrochloride, 0.201 mM L-methionine, 0.4 mM L-phenylalanine, 0.348 mM L-proline, 0.4 mM L-serine, 0.798 mM L-Threonine, 0.0784 mM, L-Tryptophan, 0.462 mM, L-Tyrosine disodium dihydrate, 0.803 mM, L-Valine, 0.0000533 mM, Biotin, 0.0286 mM, Choline chloride, 0.00839 mM, D-Calcium pantothenate, 0.00907 mM, Folic acid, 0.0328 mM, Nicotinamide, 0.0196 mM, Pyridoxal hydrochloride, 0.00106 mM, Riboflavin, 0.119 mM, Thiamine hydrochloride, 0.0000096 mM, Vitamin B12, 0.04 mM, i-Inositol, 1.49 mM, Calcium chloride anhydrous, 0.84 mM, Magnesium sulfate anhydrous, 4.4 mM, Potassium chloride, 0.000752 mM Potassium nitrate, 36 mM sodium bicarbonate, 77.59 mM sodium chloride, 0.906 mM sodium dihydrogen phosphate monohydrate, 0.0000658 mM sodium selenite pentahydrate, 25 mM D-glucose, 25.03 mM HEPES, 0.0399 mM phenol red, 1 mM sodium pyruvate.
[0069] A particularly preferred culture medium for use in step (C) is a culture medium obtained by adding iron ions and an iron transporter to a particularly preferred basal culture medium for use in step (C), and more preferably, a culture medium obtained by adding iron-binding transferrin as the sole active ingredient to a particularly preferred basal culture medium for use in step (C).
[0070] The culture medium in step (C) may contain TPO, bovine serum albumin (BSA), LDL cholesterol, insulin, 2-β-mercaptoethanol, etc., but omitting such components provides greater benefits, such as enabling the production of the platelet-like cell population of the present invention at lower cost. Specifically, MKLI culture medium, a conventional culture medium for inducing differentiation into megakaryocytic cells, contains, in addition to IMDM culture medium, TPO, BSA, LDL cholesterol, insulin, and 2-β-mercaptoethanol (hereinafter, these components are also collectively referred to as the "five components") (Matsubara Y, Murata M, Ikeda Y. Culture of megakaryocytes and platelets from subcutaneous adipose tissue and a preadipocyte cell line. Methods Mol Biol. 2012; 788: 249-258.). Eliminating these five components in the culture medium in step (C) enables the production of the platelet-like cell population of the present invention at lower cost. The present inventors have experimentally confirmed that BSA, LDL cholesterol, insulin, and 2-β-mercaptoethanol are not necessary when inducing differentiation of ASCLs into megakaryocytes or platelets. Among the culture media in step (C) (i.e., "culture media for inducing differentiation into megakaryocytic cells containing iron ions and an iron transporter"), a culture medium that does not contain bovine serum albumin, LDL cholesterol, deoxyribonucleotide triphosphate, or 2-mercaptoethanol, but contains human serum albumin, iron-binding transferrin, insulin, and monothioglycerol, is referred to herein as a "modified culture medium for inducing differentiation into megakaryocytic cells." Note that, if ASCLs can take up iron ions in the culture medium even in the absence of an iron transporter, the culture medium used in the present invention can also be referred to as a "culture medium for inducing differentiation into megakaryocytic cells containing iron ions" rather than a "culture medium for inducing differentiation into megakaryocytic cells containing iron ions."
[0071] Particularly preferred embodiments of the culture medium in step (C) include a culture medium obtained by adding human serum albumin, iron-binding transferrin, insulin, and monothioglycerol to a particularly preferred basal culture medium used for the culture medium in step (C), and further include a culture medium that does not contain bovine serum albumin, LDL cholesterol, deoxyribonucleotide triphosphate, or 2-mercaptoethanol.More specific examples include a modified MKLI culture medium having the following composition, and a culture medium containing each component at a concentration that is independently within the range of 70% to 130% (preferably within the range of 80 to 120% by weight) of the concentration of each component in the culture medium. The modified MKLI culture medium can be prepared by adding 2 mM L-glutamine (Life Technologies), 100 U / mL penicillin-streptomycin solution (Life Technologies), 0.5% human serum albumin (Sigma), 200 μg / mL iron-saturated transferrin (Sigma), 10 μg / mL insulin (Sigma), and 20 μM monothioglycerol (Wako) to IMDM culture medium (Iscove's Modified Dulbecco's Medium, Life Technologies). A modified MKLI culture medium of this composition, or a culture medium containing each component independently at a concentration within the range of 70% to 130% (preferably within the range of 80 to 120% by weight) of the concentration of each component in the culture medium, is preferably included in the "modified culture medium for inducing differentiation into megakaryocytic cells." The modified MKLI culture medium differs from the conventional MKLI culture medium in that it uses human serum albumin instead of BSA, does not use LDL cholesterol, does not use dNTPs, and uses monothioglycerol instead of mercaptoethanol.
[0072] In the above step (C), the conditions for culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a differentiation-inducing culture medium containing iron ions and an iron transporter into megakaryocytic cells are not particularly limited as long as the platelets of the present invention can be produced by culturing ASCL in the culture medium in step (C), but the culture temperature can typically be in the range of 12 to 45°C, preferably in the range of 15 to 37°C, and the culture period can typically be in the range of 4 to 25 days, preferably in the range of 5 to 17 days, and can also be in the range of 8 to 17 days.
[0073] The production method of the present invention preferably further includes a step of increasing the cell number by maintaining the cell line of the present invention before culturing the cell line in the culture medium in step (C). As described below, including such a maintenance culture step increases the number of cells of the cell line of the present invention that can be used for culture in the culture medium in step (C), thereby significantly increasing the yield of platelets of the present invention relative to the number of cells of the cell line of the present invention initially prepared. The culture medium used for such maintenance culture is not particularly limited as long as it is a culture medium that can grow the cell line of the present invention. Examples include the aforementioned basal culture medium for mesenchymal cell culture (containing no iron ions or iron transporters). When performing maintenance culture, it is preferable to use a basal culture medium for mesenchymal cell culture containing serum or serum components. During the maintenance culture step, it is preferable to appropriately perform passaging and culture medium replacement.
[0074] The method for collecting the platelets of the present invention from the culture in step (C) is not particularly limited, and examples thereof include a method of separating a culture supernatant containing the platelets of the present invention from the culture, and a method of separating the platelets of the present invention based on molecular size using a filter or the like.
[0075] The method for producing platelets of the present invention may further include, when or after collecting the platelets of the present invention from a culture, (a) a step of selecting platelets having a specific cell surface marker profile from the platelets of the present invention (i.e., platelets expressing a specific cell surface marker profile or a specific combination of cell surface markers) using the presence or absence of a specific cell surface marker or a specific combination of cell surface markers as an indicator, or (b) a step of increasing or decreasing the proportion of platelets having a specific cell surface marker profile among the platelets of the present invention, but from the viewpoint of simplicity, etc., it is preferable not to include such a step. The proportion of platelets expressing a specific cell surface marker or a specific combination of cell surface markers among platelets that have undergone such a selection step or an increase or decrease step includes the proportion of cells positive for the specific cell surface markers listed herein, or all combinations of such proportions.
[0076] (a) The method for selecting platelets having a specific cell surface marker profile from the platelets of the present invention, and (b) the method for increasing or decreasing the proportion of platelets having a specific cell surface marker profile among the platelets of the present invention are not particularly limited. However, from the viewpoint of more simply and quickly selecting platelets having a desired cell surface marker profile or increasing or decreasing the proportion of platelets having a desired cell surface marker profile, a preferred example is a method for selecting platelets having a specific cell surface marker profile using antibodies (preferably labeled antibodies, more preferably fluorescently labeled antibodies) against each of the above-mentioned cell surface markers and using the presence or absence of specific binding of each antibody as an indicator.
[0077] The phrase "selecting using the presence or absence of specific antibody binding as an indicator" means that, for positive cell surface markers in the profile, platelets to which an antibody against the marker specifically binds are selected, and for negative cell surface markers in the profile, platelets to which an antibody against the marker does not specifically bind are selected. The method for selecting platelets having a specific cell surface marker profile using the presence or absence of specific antibody binding as an indicator is not particularly limited, but includes methods using a cell sorter, magnetic beads, a cell adsorption column, etc., with the cell sorter method being preferred because it is simpler and faster. The cell sorter method is based on flow cytometry and is well known to those skilled in the art. Specific methods are described in the instruction manual for the cell sorter as well as in JP-A-2009-513161. Methods using magnetic beads are well known to those skilled in the art, such as magnetic separation methods. Specific examples include contacting magnetic beads carrying a specific antibody with cells and then recovering the magnetic beads with a magnet to separate platelets that specifically bind to the specific antibody. Furthermore, methods using cell adsorption columns are well known to those skilled in the art, and a specific example of such a method is to contact platelets with a cell adsorption column carrying a specific antibody, and allow platelets other than the target platelets to be adsorbed onto the column.
[0078] A particularly preferred embodiment of the method for producing platelets of the present invention further has one or both of the following features, from the viewpoints of simplicity and achieving a better therapeutic effect on tendon disorders: after obtaining an adipose tissue-derived mesenchymal stem cell line in step (B), and before culturing the cell line in a differentiation-inducing medium containing iron ions and an iron transporter into megakaryocytic cells in step (C), no cell selection is performed in the cell line based on the presence or absence of expression of a specific cell surface marker; the method for collecting platelets from the culture in step (C) does not include cell selection based on the presence or absence of expression of a specific cell surface marker;
[0079] The platelets of the present invention co-express one or more platelet surface markers and one or more mesenchymal cell surface markers.
[0080] In the present invention, the term "platelet population co-expressing one or more types of platelet surface markers and one or more types of mesenchymal cell surface markers" refers to a platelet population containing platelets expressing one or more types of platelet surface markers (platelets that are positive for one or more types of platelet surface markers) and platelets expressing one or more types of mesenchymal cell surface markers (platelets that are positive for one or more types of mesenchymal cell surface markers). The platelet population may contain platelets that are positive for one or more types of platelet surface markers and platelets that are positive for one or more types of mesenchymal cell surface markers, respectively, as separate platelets. However, the platelet population is preferably a platelet population that is positive for one or more types of platelet surface markers and at least partially contains platelets that are positive for one or more types of mesenchymal cell surface markers.
[0081] In the present invention, the platelet population containing "platelets expressing one or more types of platelet surface markers (platelets positive for one or more types of platelet surface markers)" is not particularly limited as long as it is a platelet population containing platelets expressing at least CD29, but preferably includes a platelet population containing platelets further expressing one or more types of platelet surface markers (preferably three types) selected from the group consisting of CD49b, CD42b, and CD41. In the present invention, a "platelet population containing platelets expressing two or more types of platelet surface markers" refers to a platelet population containing platelets expressing any one of the two or more types of platelet surface markers (platelets that are positive for any one type of platelet surface marker) and platelets expressing any one or more other types of platelet surface markers (platelets that are positive for any one or more other types of platelet surface markers). The platelet population may contain only platelets that are positive for any one type of platelet surface marker and platelets that are positive for any one or more other types of platelet surface markers, but is preferably a platelet population that contains, at least in part, platelets that are positive for any one type of platelet surface marker and are positive for any one or more other types of platelet surface markers.
[0082] Specific examples of platelet populations containing platelets expressing the platelet surface marker CD29 include platelet populations in which the proportion of CD29-positive platelets is preferably 60% or more, more preferably 70% to 90%, and even more preferably 75% to 85%. Specific examples of platelet populations containing platelets expressing one or more (preferably three) platelet surface markers selected from the group consisting of CD49b, CD42b, and CD41 in addition to CD29 include platelet populations in which the proportion of positive platelets for one or more (preferably three) platelet surface markers selected from the group consisting of CD49b, CD42b, and CD41 satisfies the following numerical ranges: The percentage of CD49b-positive platelets is preferably 30% or more (more preferably 30-85%, even more preferably 30-70%); the percentage of CD42b-positive platelets is preferably 5% or more (more preferably 6-80%, even more preferably 7-60%, even more preferably 8-40%); the percentage of CD41-positive platelets is preferably 20% or more (more preferably 20-85%, even more preferably 30-70%);
[0083] In the present invention, the platelet population containing "platelets expressing one or more types of mesenchymal cell surface markers (platelets positive for one or more types of mesenchymal cell surface markers)" is not particularly limited as long as it is a platelet population containing platelets expressing at least CD90, but preferably includes a platelet population containing platelets further expressing one or more types (preferably three or more, more preferably five or more, even more preferably seven or more, more preferably eight) of mesenchymal cell surface markers selected from the group consisting of CD13, CD26, CD44, CD73, CD77, CD81, CD95, and CD164. In the present invention, a "platelet population containing platelets expressing two or more types of mesenchymal cell surface markers" refers to a platelet population containing platelets expressing any one of the two or more types of mesenchymal cell surface markers (platelets that are positive for any one type of mesenchymal cell surface marker) and platelets expressing any one or more other types of mesenchymal cell surface markers (platelets that are positive for any one or more other types of mesenchymal cell surface markers). The platelet population may contain only platelets that are positive for any one type of mesenchymal cell surface marker and platelets that are positive for any one or more other types of mesenchymal cell surface markers, as separate platelets, but is preferably a platelet population that contains at least a portion of platelets that are positive for any one type of mesenchymal cell surface marker and any one or more other types of mesenchymal cell surface markers.
[0084] Specific examples of platelet populations containing platelets expressing the mesenchymal cell surface marker CD90 include platelet populations in which the percentage of CD90-positive platelets is preferably 30% or more, more preferably 30% to 90%, and even more preferably 35% to 70%. Furthermore, preferred examples include platelet populations in which the percentage of positive platelets for one or more (preferably three or more, more preferably five or more, even more preferably seven or more, and more preferably eight) mesenchymal cell surface markers other than CD90 are selected from the group consisting of CD13, CD26, CD44, CD73, CD77, CD81, CD95, and CD164, satisfying the following numerical ranges: The percentage of CD13-positive platelets is 30% or more (preferably 30-80%, more preferably 35-65%); The percentage of CD26-positive platelets is 15% or more (preferably 15-60%, more preferably 20-45%); The percentage of CD44-positive platelets is 30% or more (preferably 30-80%, more preferably 35-65%); The percentage of CD73-positive platelets is 40% or more (preferably 40-95%, more preferably 45-80%); The percentage of CD95-positive platelets is 20% or more (preferably 20-70%, more preferably 25-55%); The percentage of CD164-positive platelets is 15% or more (preferably 15-55%, more preferably 20-40%);
[0085] As described above, the platelet population of the present invention preferably includes a platelet population that is positive for one or more platelet surface markers and contains at least a portion of platelets that are positive for one or more mesenchymal cell surface markers, and specifically, preferably includes a platelet population that satisfies the following percentage of positive platelets: the percentage of platelets that are positive for CD42b and CD90 is 3% or more (preferably 3 to 80%, more preferably 5 to 40%, and even more preferably 5 to 20%);
[0086] A preferred embodiment of the platelet population of the present invention further includes a platelet population in which the expression of one or more specific platelet surface markers (hereinafter also referred to as "low-expressed platelet surface markers") is reduced compared to the expression thereof in a normal platelet population. A "platelet population in which the expression of one or more low-expressed platelet surface markers is reduced compared to the expression thereof in a normal platelet population" refers to a platelet population in which the proportion of platelets positive for one or more low-expressed platelet surface markers is lower than the proportion in a normal platelet population. Examples of such "low-expressed platelet surface markers" include one or more (preferably three or more, more preferably five or more) markers selected from the group consisting of CD9, CD36, CD41 / 61, CD61, and CD147. CD41 / 61 refers to a complex of CD41 and CD61, and CD41 / 61-positive platelets refer to platelets expressing the CD41 and CD61 complex.
[0087] A preferred example of a platelet population in which the expression of one or more low-expression platelet surface markers is reduced compared to the expression thereof in a normal platelet population is a platelet population in which the proportion of positive platelets satisfies the following numerical ranges for one or more (preferably three or more, more preferably five or more) low-expression platelet surface markers selected from the group consisting of CD9, CD36, CD41 / 61, CD61, and CD147: The percentage of CD9-positive platelets is 30% or less (preferably 0-20%, more preferably 0.5-15%); The percentage of CD36-positive platelets is 40% or less (preferably 0-30%, more preferably 0.5-20%); The percentage of CD41 / 61-positive platelets is 60% or less (preferably 0-40%, more preferably 0.5-25%); The percentage of CD61-positive platelets is 30% or less (preferably 0-10%, more preferably 0.1-8%); The percentage of CD147-positive platelets is 50% or less (preferably 0-40%, more preferably 1-30%);
[0088] A preferred embodiment of the platelet population of the present invention is a platelet population that contains platelets positive for one or more platelet surface markers and platelets positive for one or more mesenchymal cell surface markers, and further contains platelets positive for one or two of the activated platelet surface markers CD107a and CD107b. Platelets positive for activated platelet surface markers may be platelets separate from platelets positive for one or more platelet surface markers or platelets positive for one or more mesenchymal cell surface markers. However, the platelet population of the present invention is preferably a platelet population that at least partially contains platelets positive for activated platelet surface markers and one or more platelet surface markers, or platelets positive for activated platelet surface markers and one or more mesenchymal cell surface markers.
[0089] Specific examples of platelet populations containing platelets positive for one or two of the activated platelet surface markers CD107a and CD107b include platelet populations that satisfy the following ranges of the percentage of positive platelets for one or two of the activated platelet surface markers CD107a and CD107b: the percentage of CD107a-positive platelets is 15% or more (more preferably 25-80%, even more preferably 45-70%); the percentage of CD107b-positive platelets is 10% or more (more preferably 15-70%, even more preferably 20-55%);
[0090] The platelet population of the present invention may be (a) a platelet population in which platelets having a specific cell surface marker profile (i.e., platelets expressing a specific or specific combination of cell surface markers) have been selected, or (b) a platelet population in which the proportion of platelets having a specific cell surface marker profile has been increased or decreased, using the presence or absence of a specific or specific combination of cell surface markers as an indicator. In such a platelet population, the proportion of platelets expressing a specific or specific combination of cell surface markers includes the proportion of platelets positive for the specific cell surface markers listed herein, or any combination of such proportions.
[0091] In a preferred embodiment of the platelet population of the present invention, the amount of TGF-β (transforming growth factor β) produced by the platelet population measured by the following measurement method is 1×10 8 Examples of the platelet population include a platelet population having a TGF-β production level of 0.1 pg or more, preferably 1 pg or more, more preferably 2.5 pg or more, even more preferably 5 pg or more, more preferably 7.5 pg or more, even more preferably 10 pg or more, and even more preferably 15 pg or more per platelet. (Method for measuring the amount of TGF-β produced) 8 Platelets were collected in phosphate-buffered saline containing 10 mM CaCl 2 After 15 minutes of incubation, the amount of TGF-β in the phosphate buffered saline solution is measured. The PBS solution used for the suspension contains 8 g / L NaCl, 0.2 g / L KCl, 1.44 g / L NaCl, and 2 HPO 4 , 0.24g / LKH 2 P.O. 4 (pH 7.4) is preferred.
[0092] The platelets of the present invention do not necessarily have to be calcium-stimulated, but calcium-stimulated platelets are preferred from the viewpoint of achieving a greater therapeutic effect on tendon disorders. The calcium stimulation method is not particularly limited, but includes incubating the platelets of the present invention in a solution with a calcium concentration of, for example, 0.01 to 100 mM, preferably 0.5 to 50 mM, and more preferably 5 to 20 mM. The incubation time is not particularly limited, but includes, for example, 0.1 minutes to 3 hours, preferably 10 to 20 minutes. The calcium-containing compound used for calcium stimulation is not particularly limited, but includes calcium salts such as calcium chloride. The timing of calcium stimulation is also not particularly limited, but includes, for example, before administration of the platelets of the present invention, within 5 hours, 3 hours, 1 hour, or 30 minutes prior to administration.
[0093] (Therapeutic Agent for Tendinopathy of the Present Invention) The therapeutic agent of the present invention is not particularly limited as long as it contains the platelets of the present invention as an active ingredient. The therapeutic agent of the present invention can be prepared, stored, and administered in a similar manner, taking into account findings from conventionally known cell preparations, etc. The therapeutic agent of the present invention is typically in the form of an injection. The therapeutic agent of the present invention can be administered to the site of an injured tendon (e.g., the Achilles tendon) of a target vertebrate (preferably a human patient). The therapeutic agent of the present invention can be prepared in a form suitable for administration to a subject by, for example, mixing the platelets of the present invention with a pharmaceutically acceptable carrier. Examples of carriers include saline, distilled water for injection made isotonic by adding glucose or other adjuvants (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.). Furthermore, buffers (e.g., phosphate buffer, sodium acetate buffer), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g., human serum albumin, polyethylene glycol, etc.), preservatives, antioxidants, etc. may be added. The therapeutic agent of the present invention can also be used as a composition for treating tendinopathy.
[0094] The therapeutic agent of the present invention may further contain, in addition to the platelets of the present invention, various commonly used additive components and other drugs effective in treating tendon disorders, as necessary.
[0095] The subjects for the treatment of tendon disorders in the present invention are not particularly limited as long as they are vertebrates, and examples thereof include mammals, birds, reptiles, amphibians, fish, etc., of which mammals such as humans, mice, rats, guinea pigs, rabbits, cats, dogs, horses, cows, monkeys, sheep, goats, and pigs are preferred, and humans are particularly preferred.
[0096] As used herein, the term "tendinopathy" is not particularly limited as long as it is a disorder of a tendon, and examples thereof include tendinosis, tendinitis, tenosynovitis, etc. More specifically, preferred examples of tendinopathy include tendinopathy selected from the group consisting of Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis, medial epicondylitis, plantar fasciitis, and rotator cuff tendinopathy.
[0097] As used herein, treating tendinopathy includes not only improving the symptoms of tendinopathy, but also inhibiting or delaying the worsening of the symptoms of tendinopathy.
[0098] The dose per administration of the therapeutic agent of the present invention is not particularly limited as long as it has a therapeutic effect on tendinopathy, and can be appropriately determined by a person skilled in the art, taking into consideration the degree of tendinopathy in the patient, the extent of the area of tendinopathy, etc. For example, the platelets of the present invention may be administered in a single dose of 1 x 10 5 ~1 x 10 11 The therapeutic agent of the present invention can be administered once or twice or more times. The number of times the therapeutic agent of the present invention is administered is not particularly limited as long as a therapeutic effect against tendinopathy is obtained, and since an excellent therapeutic effect can be obtained even with a single administration, the therapeutic agent may be administered once or twice or more times. Examples of twice or more administrations include 1 to 7 times, 1 to 5 times, 1 to 3 times, and 1 to 2 times. When the therapeutic agent of the present invention is administered twice or more times, the administration interval from the previous administration can be appropriately determined depending on the symptoms of the joint of the target vertebrate, and examples include an interval within a range of 3 to 6 weeks, or an interval within a range of 6 months to 1 year.
[0099] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
[0100] 1. [Production of ASCL] Adipose-derived mesenchymal stem cell lines (ASCL) were prepared according to the method described in the Examples of International Publication WO 2017 / 094260. Adipose tissue-derived stem cells (ADSCs) were obtained from Cell Applications.
[0101] 2. [Production of Platelets of the Present Invention] The ASCL obtained above were cultured in a modified MKLI culture medium for 14 days to differentiate the ASCL into platelets. Platelets were collected from the culture medium and used as platelets of the present invention (hereinafter referred to as "ASCL-PLC").
[0102] 3. [Preparation of PRP] PRP for use in the control group was prepared by collecting peripheral blood and centrifuging it at 200 G for 10 minutes and then at 1500 G for 10 minutes to obtain PRP.
[0103] 4. [Creation of a rat tendon injury model] To confirm the anti-inflammatory effects of platelets in the present invention, a tendon injury model capable of reliably inducing a certain level of inflammation was used. Ten-week-old male Wistar rats were used. The right leg was designated as the sham side, and the Achilles tendon sheath was incised but not excised near the Achilles tendon insertion site (negative control). On the other hand, the left leg was designated as the incision side, and the Achilles tendon sheath was incised and excised near the Achilles tendon insertion site.
[0104] 5. [Analysis of inflammatory cytokine expression in a tendon injury model] The anti-inflammatory effect was verified by analyzing the expression levels of inflammatory cytokines using RT-PCR in a tendon injury model. Three days after the creation of the tendon injury model rats, the rats were sacrificed, and the expression levels of inflammatory cytokines (i.e., IL-6 and IL-1b) were analyzed by RT-PCR in the incision and sham legs. Total RNA was extracted from the Achilles tendon using TRI Reagent (TR118, Molecular Research Center, Inc., Cincinnati, OH) and the Rneasy Mini Kit (74106, QIAGEN, Hamburg, Germany). Reverse transcription was performed using the Advantage RT-for-PCR Kit (Takara Bio Inc., Otsu, Shiga Prefecture), and cDNA was synthesized. Real-time PCR (intercalator method) was performed using SYBR PremixExTaq II (Takara Bio) in a DICE thermal cycler (Takara Bio) according to the manufacturer's instructions. The primers used were as follows. The RT-PCR results showed significantly higher expression of both inflammatory cytokines, IL-6 and IL-1b, in the incision-side leg compared to the sham-side leg. This confirmed that inflammation was significantly induced in the incision-side leg compared to the sham-side leg in tendon injury model rats. Of these inflammatory cytokines, IL-6, which showed the most consistent results, was used as the target for subsequent experiments to evaluate its anti-inflammatory effects. (Primer set for rat IL-6) Forward primer (F): TCTCTCCGCAAGAGACTTCCA (SEQ ID NO: 1) Reverse primer (R): GGTCTGTTGTGGGTGGTATCC (SEQ ID NO: 2) (Primer set for rat IL-1b) Forward primer (F): TGTGATGTTCCCATTAGAC (SEQ ID NO: 3) Reverse primer (R): AATACCACTTGTTGGCTTA (SEQ ID NO: 4)
[0105] In each tendon injury model rat, the right leg was designated as the sham side and the left leg as the incision side. After the area near the Achilles tendon insertion was excised, the wound was closed and 1.0 × 10 7 50 μL of PRP containing 1.0 × 10 platelets (PRP administration group; control group), or 7 50 μL of ASCL-PLC containing platelets (ASCL-PLC administration group) was administered. Before administration, both ASCL-PLC and PRP were dissolved in PBS (phosphate buffered saline) containing 10 mM CaCl 2 The rats were then incubated for 15 minutes at 500°C for calcium stimulation. Three days after administration, each rat was sacrificed, and the expression levels of IL-6 in the sham and incision limbs were analyzed by RT-PCR. The results are shown in Figure 1.
[0106] As can be seen from Figure 1, the expression level of IL-6 was significantly suppressed in the ASCL-PLC-administered group compared to the PRP-administered group (control group). This indicates that inflammation caused by tendinopathy is significantly suppressed when the platelets of the present invention are used compared to when PRP is used. These results demonstrate that the therapeutic effect of tendinopathy using ASCL-PLC is significantly superior to the therapeutic effect of tendinopathy using the conventional method of PRP.
[0107] 6. [Confirmation of the in vitro anti-inflammatory effect of ASCL-PLC] To confirm how the anti-inflammatory effect of ASCL-PLC compares with that of PRP, the following in vitro experiment was conducted, focusing on TGF-β, which also has anti-inflammatory activity.
[0108] 1 x 10 8 10mM CaCl 2 After stimulation by incubation with 1×10 for 15 minutes, the amount (pg) of TGF-β released into PBS by activation of the platelets was measured. 8 PRP containing 1000 platelets was dissolved in PBS (phosphate buffered saline) containing 10 mM CaCl 2After 15 minutes of incubation, the amount of TGF-β (pg) in the PBS was measured using a commercially available ELISA kit. The results of the TGF-β measurement are shown in FIG. 2.
[0109] As can be seen from Figure 2, platelets contained in PRP did not produce TGF-β in response to cell stimulation with calcium, but ASCL-PLC was shown to produce TGF-β in response to cell stimulation with calcium. These results demonstrate that the therapeutic effect of tendinopathy using ASCL-PLC is significantly superior to the therapeutic effect of tendinopathy using the conventional method of PRP.
[0110] 7. [Creation of a Tendon Degeneration Model Rat] A tendon degeneration model was used to confirm the effect of platelets in the present invention, primarily on tendon repair. 50 μL of collagenase type 1 (500 UI), which has a tendon degeneration effect, was administered to both legs of 8-week-old rats. Two weeks later, rats in which degeneration had progressed sufficiently were used as tendon degeneration model rats.
[0111] 8. [Maximum Breaking Load Test] In tendon degeneration model rats, 50 μL of PBS was administered to the right leg as a control, and 50 μL of ASCL-PLC was administered to the left leg. Two and four weeks after administration of ASCL-PLC or PBS, the rats were sacrificed. The Achilles tendons with the calcaneus were harvested from the sacrificed rat legs, and both stumps were held with a load cell and subjected to traction stress. The strength at break was compared. The results of the maximum breaking load test two weeks after administration of ASCL-PLC or PBS are shown in the left panel of Figure 3, and the results four weeks after administration are shown in the right panel of Figure 3.
[0112] As can be seen from FIG. 3, the maximum strength of the Achilles tendon was improved in the ASCL-PLC administration group compared to the control group, and a significant improvement was observed after 4 weeks.
[0113] 9. [Histological Evaluation] In tendon degeneration model rats, 50 μL of PBS was administered to the right leg as a control, and 50 μL of ASCL-PLC was administered to the left leg. One, two, and four weeks after administration, the rats were sacrificed. The sacrificed rats' legs were fixed in formalin so that the Achilles tendons were elongated. The fixed Achilles tendons were stained with hematoxylin and eosin (HE), Alcian Blue, and Picrocirius Red.
[0114] The results of HE staining of the fixed Achilles tendon are shown in Figure 4, and the results of Alcian blue staining are shown in Figure 5. Furthermore, the results of picrosirius red staining of the fixed Achilles tendon and observation under a polarizing microscope are shown in Figure 6. The results of HE staining confirmed that collagen alignment was improved in the ASCL-PLC-administered group compared to the PBS-administered group (control group). Furthermore, the results of Alcian blue staining confirmed that the degree of staining was lighter in the ASCL-PLC-administered group compared to the PBS-administered group (control group), confirming that tendon degeneration had improved. Furthermore, the results of picrosirius red staining confirmed that the ASCL-PLC-administered group had more uniform staining compared to the PBS-administered group (control group), confirming that tendon degeneration had improved.
[0115] Furthermore, the Bonar score was calculated from the results of hematoxylin-eosin staining and Alcian blue staining, and the results of the PBS-treated group (control group) and the ASCL-PLC-treated group were compared at each week after administration. The results are shown in Figure 7. The Bonar score is known as the most common method for pathological evaluation of tendons (e.g., Jaworski, et al.; J Clin Med. 2022 Mar 13; 11(6); 1572).
[0116] As can be seen from Figure 7, 4 weeks after administration, the Bonar score was significantly reduced in the ASCL-PLC group compared to the PBS-administered group (control group), and histologically, it was confirmed that tendon damage had significantly improved.
[0117] 10. [Analysis of the expression levels of tendon-related cytokines in a rat model of tendon degeneration] The effect of improving tendon disorders was verified by analyzing the expression levels of tendon-related cytokines using RT-PCR in a rat model of tendon degeneration. The tendon-related cytokines used were Col-1 (type 1 collagen), Col-3 (type 3 collagen), SCX (scleraxis), and TNC (tenascin C).
[0118] In tendon degeneration model rats, 50 μL of PBS was administered to the right leg as a control, and 50 μL of ASCL-PLC was administered to the left leg. One, two, and four weeks after administration, the tendon degeneration model rats were sacrificed, and the expression levels of tendon-related cytokines (i.e., Col-1, Col-3, SCX, and TNC) were analyzed by RT-PCR in the ASCL-PLC-administered group (left leg) and the control (PBS-administered) group (right leg). RT-PCR (intercalator method) was performed using the primers listed below, using the same method as described in Section 5 of the Examples above. The results of this RT-PCR are shown in Figure 8. (Primer set for rat collagen Type 1) Forward primer (F): GCGTAGCCTACATGGACCAACAG (SEQ ID NO: 5) Reverse primer (R): AAGTTCCGGTGTGACTCGTGCAG (SEQ ID NO: 6) (Primer set for rat collagen Type 3) F: TCGGGATCTGTCCTCTGTGATGA (SEQ ID NO: 7) R: CAGGAATGACAGGAGCAGGTGTA (SEQ ID NO: 8) (Primer set for rat SCX) F: AGCAACCAGAGAAAGTTGAGCAAAG (SEQ ID NO: 9) R: TTCCACCTTCACTAGTGGCATC (SEQ ID NO: 10) (Primer set for rat TNC) F: TGATGGAGGTGGATGGATCGTT (SEQ ID NO: 11) R: CTCAGGTTATCCAGTCCAAGCCA (SEQ ID NO: 12)
[0119] As can be seen from Figure 8, the ASCL-PLC group showed significantly increased expression levels of Col-1, Col-3, SCX, and TNC at 4 weeks after administration compared to the PBS-administered group (control group). These results confirmed that the ASCL-PLC group had improved tendon degeneration repair ability compared to the PBS-administered group (control group).
[0120] 11. [Confirmation of the Tendon Repair Effect of ASCL-PLC in Vitro] To confirm the tendon repair effect of ASCL-PLC, the following in vitro experiment using tenoblasts was carried out.
[0121] 1 x 10 8 Tendonoblasts were exposed to PBS (phosphate-buffered saline) containing 1000p of ASCL-PLC for 3, 6, or 12 hours, and the amount of Col-1 in the PBS was then measured. A control experiment was also performed in the same manner without ASCL-PLC, and the amount of Col-1 was measured. The results are shown in Figure 9.
[0122] As can be seen from Figure 9, the use of ASCL-PLC significantly increased Col-1 expression 6 and 12 hours after treatment, demonstrating that ASCL-PLC has the effect of promoting tenoblast differentiation.
[0123] According to the present invention, it is possible to provide a therapeutic agent for tendon disorders that uses platelets produced from a specific adipose tissue-derived mesenchymal stem cell line (ASCL), and that has a stable and excellent therapeutic effect on tendon disorders. Furthermore, because the platelets of the present invention are prepared from ASCL, they have advantages such as the ability to be mass-cultured and cryopreserved.
Claims
1. A therapeutic agent for tendon disorders, comprising as an active ingredient platelets produced by a manufacturing method comprising the following steps (A) to (C): (A) a step of inducing differentiation into mature adipocytes of one or more types of cells selected from a stromal vascular cell group including mesenchymal stem cells, preadipocytes and stromal cells of vertebrate adipose tissue; (B) a step of inducing dedifferentiation of the mature adipocytes obtained in step (A) to obtain a vertebrate adipose tissue-derived mesenchymal stem cell line; (C) a step of culturing the adipose tissue-derived mesenchymal stem cell line obtained in step (B) in a differentiation-inducing medium into megakaryocyte lineage cells containing iron ions and an iron transporter, and collecting platelets from the culture; 2. The therapeutic agent according to claim 1, wherein the step of inducing differentiation of one or more types of cells into mature adipocytes in step (A) is a step of culturing the one or more types of cells in a basic culture medium for mesenchymal cell culture containing one or more types of adipocyte differentiation inducers selected from the group consisting of dexamethasone, isobutylmethylxanthine, insulin and serum.
3. The therapeutic agent according to claim 1, wherein inducing dedifferentiation of mature adipocytes in step (B) comprises subjecting mature adipocytes to ceiling culture.
4. The therapeutic agent described in claim 1, wherein the one or more types of cells are cells obtained by removing mature adipocytes from a cell population obtained by treating adipose tissue of a vertebrate with an enzyme capable of dispersing adipose tissue cells of a vertebrate.
5. The therapeutic agent according to claim 4, wherein the enzyme capable of dispersing adipose tissue cells of a vertebrate is one or more enzymes selected from the group consisting of collagenase, trypsin, caseinase, clostripain, trypsin-EDTA, dispase, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain.
6. The therapeutic agent according to claim 1, characterized in that the iron transporter in step (C) is transferrin.
7. The therapeutic agent according to claim 1, characterized in that the iron ions and iron transporter in step (C) are iron-binding transferrin.
8. The therapeutic agent according to claim 1, which is administered to a tendon of a vertebrate in need of treatment for tendon disorders.
9. The therapeutic agent according to claim 1, wherein the tendon disorder is selected from the group consisting of tendinosis, tendinitis, and tenosynovitis.
10. The method of claim 1, wherein the tendon disorder is selected from the group consisting of Achilles tendon disorder, patellar tendon disorder, lateral epicondylitis, medial epicondylitis, plantar fasciitis, and rotator cuff tendon disorder.
11. The therapeutic agent according to any one of claims 1 to 10, wherein the vertebrate is a human.
Citation Information
Patent Citations
Hemoglobin measuring method
JP1996029429A
Radiolabeled metal transport proteins as contrast agents
JP2004505932A
Method for radiolabeling biomolecules
JP2005517042A
Regulation of self-renewal and lineage specification of es cells and media therefor
JP2007508026A
Compositions and methods for treating and diagnosing cancer
JP2009513161A
